UK defence medical services guidance for the use of recombinant factor VIIa (rFVIIa) in the deployed military setting.
نویسندگان
چکیده
Use of recombinant Factor VIIa (rFVIIa) for trauma is currently an 'off label' use. There are reports of rFVIIa contributing to the successful outcome of military trauma patients. This paper sets out the current position of the UK Defence Medical Services with regard to using rFVIIa in military trauma.
منابع مشابه
Hemorrhage Treatment Report of Patients Suffering from Glanzmann’s Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children’s Hospital
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran. Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011. Resu...
متن کاملEffect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
OBJECTIVES Military casualties with vascular injuries often present with severe acidosis and coagulopathy that can negatively influence limb salvage decisions. We previously reported the value of a damage control resuscitation (DCR) strategy that can correct physiologic shock during simultaneous vascular reconstruction. The effect of recombinant factor VIIa (rFVIIa) on the repair of injured ves...
متن کاملRecombinant factor VIIa use in patients presenting with intracranial hemorrhage
Recombinant factor VIIa (rFVIIa) can be used for rapid INR normalization in life-threatening hemorrhage in anticoagulated patients. Dosing is unclear and may carry thromboembolic risks. We reviewed the use of rFVIIa at a comprehensive stroke and cerebrovascular center to evaluate dose effectiveness on INR reduction and thromboembolic complications experienced. The primary endpoint was to review...
متن کاملMonitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy.
OBJECTIVES Recombinant activated factor VII (rFVIIa) is increasingly being given to treat massive bleeding. However, there is no clear guidance on which patients are suitable for treatment and how the effects of treatment should be monitored. The aim of this in vitro study was to assess the coagulation status of severely hemodiluted blood samples before and after treatment with therapeutic dose...
متن کاملFailure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding
BACKGROUND This report discusses a case of unsuccessful treatment with recombinant factor VIIa (rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa is outlined as well as the need for methods to control the efficacy of rFVIIa objectively. CASE PRESENTATION 54 year old male with severe polymicrobial sepsis due to a perforated diverticulitis of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the Royal Army Medical Corps
دوره 153 4 شماره
صفحات -
تاریخ انتشار 2007